MagicRNA Announces Acceptance of Abstract and Poster Presentation at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

MagicRNA Biotech, a biotechnology company specializing in Engineered Cell-Targeted Lipid Nanoparticles (EnC-LNP) and developing therapeutic pipelines based on this platform, announced that the abstract for HN2301 data—an in vivo CAR-T producer for autoimmune diseases—has been accepted for poster presentation at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT). The meeting will take place from May 13-17, 2025, at the Ernest N. Morial Convention Center in New Orleans, LA.

Poster Presentation

Title: A Vivo CAR T Producer (HN2301) for Autoimmune Disease Enables B cell Depletion in NHP Tissues and Performs Therapeutic Effect in an SLE Mouse Model 

Session Date/Time: May 13, 2025, 6:00PM – 7:30PM(Central Time Zone, UTC-5).

Session Location: Poster Hall Hall I2

Abstract Number: 794

About MagicRNA

Shenzhen MagicRNA Biotech Co., Ltd. established in 2021, specializes in the development of advanced nucleic acid delivery technologies. MagicRNA has successfully established the Engineered Cell-Targeted Lipid Nanoparticle (EnC-LNP) platform, enabling precise and specific delivery of therapeutic agents to immune cells, central nervous system (CNS) cells, and tumor cells. Leveraging EnC-LNP platform, MagicRNA has developed pipeline with diverse therapeutic applications. As the ionizable amine lipid represents the critical component determining LNP performance, MagicRNA has established an innovative ionizable lipid library featuring a proprietary lipid structure and the core lipid, ILB-3132, which is now commercially available.

For more information, please visit www.magicrna.com. or connect:Info@magicrna.com.